Compare Coursera Inc (COUR) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Nuvalent Inc — how do they compare? Coursera Inc trades at $5.57 (market cap $1.64B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 6× Coursera Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | NUVL | |
|---|---|---|
Market Cap | $1.64B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $12.70 | $123.96 |
52-Week Low | $5.09 | $72.16 |
Enterprise Value | $890.21M | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.67, down 0.7% on the day, with technical indicators showing a bearish trend. The company reported Q1 2026 earnings of $0.07 per share, missing estimates of $0.09, but revenue growth remains positive, reaching $757.5 million in 2025. Recent news highlights the completion of the Udemy merger and a $500 million share repurchase program, while analyst sentiment is mixed with a consensus price target of $8.00.
The outlook for COUR is cautiously optimistic, driven by potential synergies from the Udemy merger and steady revenue growth, though profitability challenges and competitive pressures pose risks. With a 52.94% buy rating from analysts and a 38.5% upside to the consensus target, the stock offers growth potential, but investors should monitor execution on cost management and integration success.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
